Clinical Trial Update: Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome

View source ↗

Summary

Clinical trial update notes that a study evaluating 3,4-diaminopyridine for Lambert-Eaton myasthenic syndrome is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lambert-eaton Myasthenic Syndrome

Drugs mentioned

• 3,4-Diaminopyridine (3,4-diaminopyridine)

Snippet

Sponsor: The Cleveland Clinic | Conditions: Lambert-Eaton Myasthenic Syndrome | Status: NO_LONGER_AVAILABLE